Table 2 Summary of efficacy data

From: A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Assessment

n = 47

Best overall response, n (%)

   Partial response (PR)

21 (45)

   Stable disease (SD)

17 (36)

   Progressive disease (PD)

9 (19)

   Confirmed ORR (%)

21 (45)

Median duration of response, months

9.2 (7.4, NE)

Disease control rate (PR + SD) (%)

38 (81)

Median PFS1#, months

9.4 (7.2, 13)

Median PFS2*, months

3.8 (3.4, 5.9)

  1. #PFS1 was defined as the interval from registration to the first occasion at which progression or death occurred.
  2. *PFS2 was defined as time to progression or death on continuous dosing osimertinib, after alternating therapy was ceased.
  3. PFS progression free-survival, ORR overall response rate.
Back to article page